Detalhe da pesquisa
1.
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Lancet Oncol;
23(3): 374-381, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35157829
2.
Personalised Exercise-Rehabilitation FOR people with Multiple long-term conditions (PERFORM): protocol for a randomised feasibility trial.
BMJ Open;
14(4): e083255, 2024 Apr 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38580370
3.
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Lancet Respir Med;
9(6): 593-600, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33515503